BioDelivery Sciences International (BDSI) vs. American Oriental Bioengineering (AOBI) Critical Survey
BioDelivery Sciences International (NASDAQ:BDSI) and American Oriental Bioengineering (OTCMKTS:AOBI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
Institutional & Insider Ownership
57.0% of BioDelivery Sciences International shares are owned by institutional investors. 13.3% of BioDelivery Sciences International shares are owned by company insiders. Comparatively, 30.3% of American Oriental Bioengineering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings for BioDelivery Sciences International and American Oriental Bioengineering, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioDelivery Sciences International||0||0||5||0||3.00|
|American Oriental Bioengineering||0||0||0||0||N/A|
BioDelivery Sciences International presently has a consensus price target of $6.00, indicating a potential upside of 17.42%. Given BioDelivery Sciences International’s higher probable upside, equities analysts plainly believe BioDelivery Sciences International is more favorable than American Oriental Bioengineering.
This table compares BioDelivery Sciences International and American Oriental Bioengineering’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioDelivery Sciences International||-60.87%||-79.59%||-20.43%|
|American Oriental Bioengineering||N/A||N/A||N/A|
Volatility & Risk
BioDelivery Sciences International has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -9.96, indicating that its share price is 1,096% less volatile than the S&P 500.
Valuation and Earnings
This table compares BioDelivery Sciences International and American Oriental Bioengineering’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioDelivery Sciences International||$55.64 million||6.52||-$33.87 million||($0.73)||-7.00|
|American Oriental Bioengineering||N/A||N/A||N/A||N/A||N/A|
American Oriental Bioengineering has lower revenue, but higher earnings than BioDelivery Sciences International.
BioDelivery Sciences International beats American Oriental Bioengineering on 5 of the 9 factors compared between the two stocks.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc. is a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.
American Oriental Bioengineering Company Profile
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of pharmaceutical and healthcare products. It operates through the manufacturing and distribution segments. Its products include prescription pharmaceutical, over-the-counter pharmaceutical, and nutraceutical products. The company was founded by Shujun Liu, Yanchun Li, and Jun Min on November 30, 1970 and is headquartered in Beijing, China.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.